Literature DB >> 6879639

Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance.

D M Cocchetto, C Tschanz, T D Bjornsson.   

Abstract

Serum creatinine concentration is commonly used in conjunction with individual patient characteristics (e.g., age, sex, and body weight) in order to estimate creatinine clearance. Such estimates of creatinine clearance are widely used as a parameter for individualization of dosages of drugs excreted primarily via the kidneys in patients with diminished renal function. However, estimation of creatinine clearance in patients with concurrent hepatic disease tends to result in substantial overprediction of observed creatinine clearance in this patient population. This report suggests that a diminished rate of creatinine production in patients with hepatic disease is a likely explanation for this anomaly. This postulated mechanism is based on a presentation of the biology of creatinine formation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6879639     DOI: 10.1097/00007691-198306000-00002

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  42 in total

1.  Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.

Authors:  Tianlu Chen; Guoxiang Xie; Xiaoying Wang; Jia Fan; Yunping Qiu; Xiaojiao Zheng; Xin Qi; Yu Cao; Mingming Su; Xiaoyan Wang; Lisa X Xu; Yun Yen; Ping Liu; Wei Jia
Journal:  Mol Cell Proteomics       Date:  2011-04-25       Impact factor: 5.911

2.  Evaluation of renal cortical thickness by non-contrast-enhanced MR imaging with spatially selective IR pulses: comparison between cirrhotic and non-cirrhotic patients.

Authors:  Akihiko Kanki; Katsuyoshi Ito; Akira Yamamoto; Kazuya Yasokawa; Yasufumi Noda; Tomohiro Sato; Tsutomu Tamada
Journal:  Br J Radiol       Date:  2016-05-25       Impact factor: 3.039

3.  Predictors of Augmented Renal Clearance in a Heterogeneous ICU Population as Defined by Creatinine and Cystatin C.

Authors:  Andrea M Nei; Kianoush B Kashani; Ross Dierkhising; Erin F Barreto
Journal:  Nephron       Date:  2020-05-19       Impact factor: 2.847

4.  The accuracy of creatinine clearance with and without urine collection as a measure of glomerular filtration rate.

Authors:  D G Waller; J S Fleming; B Ramsey; J Gray
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

5.  Rapid estimation of creatinine clearances in patients with liver dysfunction.

Authors:  N P Lam; R Sperelakis; J Kuk; J D Seeger; A H Lau
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

6.  Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Authors:  Ayse L Mindikoglu; Antone R Opekun; William E Mitch; Laurence S Magder; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; Charles D Howell; Jean-Pierre Raufman; Abbas Rana; John A Goss; Saira A Khaderi; John M Vierling
Journal:  Dig Dis Sci       Date:  2018-02-01       Impact factor: 3.199

7.  Overestimation of renal function in glucocorticosteroid treated patients.

Authors:  F F Horber; J Scheidegger; F J Frey
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study.

Authors:  Clara Y Jones; Camille A Jones; Ira B Wilson; Tamsin A Knox; Andrew S Levey; Donna Spiegelman; Sherwood L Gorbach; Frederick Van Lente; Lesley A Stevens
Journal:  Am J Kidney Dis       Date:  2008-05-02       Impact factor: 8.860

9.  Nomogram for estimating creatinine clearance.

Authors:  T D Bjornsson; D M Cocchetto; F X McGowan; C P Verghese; F Sedor
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

10.  Reduced production of creatinine limits its use as marker of kidney injury in sepsis.

Authors:  Kent Doi; Peter S T Yuen; Christoph Eisner; Xuzhen Hu; Asada Leelahavanichkul; Jürgen Schnermann; Robert A Star
Journal:  J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.